For NSCLC, novel molecular agents are identified as promising therapeutic targets, including KRAS non-G12C, RAF/MEK, HER3, Nectin-4, folic acid receptor alpha, ITGB6, and PRMT5. This evidence concerns the gene KRAS and non-small cell lung carcinoma.